| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | - | - | - |
| Operating Income | ¥-4.0B | ¥-2.1B | -86.8% |
| Ordinary Income | ¥-3.9B | ¥-2.3B | -67.4% |
| Net Income | ¥-4.2B | ¥-2.4B | -80.1% |
| ROE | -23.8% | -10.7% | - |
FY2025 full-year results show expanded losses across all profit lines. Operating loss reached 4.0B yen (YoY -86.8% deterioration from -2.1B yen loss), ordinary loss 3.9B yen (YoY -67.4% from -2.3B yen), and net loss 4.2B yen (YoY -80.1% from -2.4B yen). Total assets decreased to 18.8B yen from 22.5B yen prior year, while total equity declined to 17.8B yen from 22.1B yen. Despite operating losses, the company maintains substantial cash reserves of 18.25B yen, supported by significant financing activities totaling 8.48B yen inflow during the period.
Revenue data is not disclosed in the financial statements, limiting top-line trend analysis. The operating loss expanded by 1.86B yen YoY to 4.0B yen, driven primarily by continued R&D expenditures of 2.16B yen and selling, general and administrative expenses of 2.72B yen. The company recorded an impairment loss of 0.31B yen as a non-recurring factor, contributing to the widened loss. The gap between ordinary loss of 3.9B yen and net loss of 4.2B yen reflects approximately 0.3B yen of additional non-operating and extraordinary losses. With operating income at -4.0B yen and net income at -4.2B yen, this represents a revenue down/profit down pattern, though the absence of revenue disclosure limits full characterization of the fundamental business trajectory.
[Profitability] ROE cannot be calculated due to negative net income of -4.2B yen. Operating margin is unmeasurable without revenue disclosure, but the absolute operating loss of 4.0B yen represents a significant deterioration from prior year's 2.1B yen loss. [Cash Quality] Cash and deposits stand at 18.25B yen with short-term debt coverage ratio of approximately 18.46x, indicating exceptionally strong liquidity position. [Investment Efficiency] Asset turnover cannot be calculated without revenue data. Capital expenditure of 0.26B yen against depreciation of 0.16B yen yields a capex-to-depreciation ratio of 1.61x, suggesting continued growth investment. [Financial Health] Equity ratio stands at 94.6%, improving from prior year levels, with current ratio of approximately 1846.0%, reflecting minimal short-term liquidity risk. Debt-to-equity ratio of 0.06x indicates a highly conservative capital structure with minimal leverage.
Operating cash flow of -2.99B yen reflects the ongoing operating losses, though the cash outflow is smaller than the net loss of -4.25B yen, indicating some non-cash expenses including depreciation of 0.16B yen and impairment of 0.31B yen. The operating CF to net income ratio of 0.70x suggests modest cash backing of reported losses. Investing cash flow recorded a positive 4.51B yen, primarily reflecting movements in time deposits and investment recoveries rather than asset disposals. Financing cash flow of 8.48B yen represents substantial capital raising activities during the period, maintaining the company's cash position. Free cash flow of 1.52B yen results from the combination of negative operating cash flow offset by positive investing cash flow. Working capital improved with accounts receivable declining by 0.12B yen YoY to 0.09B yen, contributing positively to cash conversion. The company's cash and deposits increased despite operating losses, supported by external financing activities.
Ordinary loss of 3.9B yen compared to operating loss of 4.0B yen indicates minimal non-operating income contribution of approximately 0.1B yen, suggesting core operations drive the reported loss without significant distortion from non-operating items. The company recorded impairment losses of 0.31B yen as extraordinary items, representing approximately 7.8% of the operating loss and classified as non-recurring. Non-operating income composition is not extensively disclosed but appears limited in scale. The operating cash flow to net income ratio of 0.70x falls below the typical threshold of 1.0x, indicating that cash outflows are somewhat smaller than accounting losses, partly due to non-cash charges including depreciation and impairment. Retained earnings deteriorated sharply from -2.03B yen to -6.29B yen, reflecting accumulated losses that warrant attention regarding future capital policy flexibility.
Full-year forecast projects operating loss of 5.69B yen, ordinary loss of 5.64B yen, and net loss of 5.67B yen. Actual results through fiscal year-end show operating loss of 4.0B yen, representing approximately 70% of the forecasted loss, suggesting performance slightly better than the full-year trajectory implied by the guidance. The forecast indicates expectations for continued and expanded losses in the upcoming period, with operating loss projected to increase by approximately 1.7B yen from current year actuals. The company forecasts zero dividend per share, consistent with the loss-making status. Earnings per share is projected at -87.44 yen compared to actual -65.62 yen in the current period, indicating an anticipated deepening of per-share losses.
Operating cash flow generation weakness represents a critical risk, with operating CF of -2.99B yen and an operating CF to net income ratio of 0.70x indicating that the business requires continued external funding to sustain operations and R&D activities. The cumulative deficit in retained earnings expanded to -6.29B yen from -2.03B yen, representing a 209% deterioration that constrains future dividend capacity and may eventually require additional capital measures if losses persist. The company's forecasted operating loss of 5.69B yen for the next period, representing a further 43% increase from current year's 4.0B yen loss, indicates near-term profitability remains elusive and extends the timeline to cash flow breakeven.
Industry benchmark data is limited for this specialized biotechnology research company. The company operates in the pharmaceutical research and development sector, characterized by extended development timelines, substantial upfront R&D investments, and binary commercialization outcomes. Compared to early-stage biotech peers, Veritas In Silico maintains an exceptionally strong balance sheet with an equity ratio of 94.6% and cash coverage exceeding industry norms, providing financial runway to pursue development objectives. The company's R&D intensity, while absolute revenue is undisclosed, represents the primary cost driver consistent with pre-commercial biotechnology firms. The ability to access financing markets, evidenced by 8.48B yen in financing cash inflows, positions the company comparably to venture-stage peers requiring periodic capital raises. Source: Proprietary analysis of publicly available biotech sector financials.
Operating losses expanded significantly to 4.0B yen from 2.1B yen YoY, driven by sustained R&D expenditures of 2.16B yen, indicating the company remains in active development phase with commercialization not yet achieved. The company maintains substantial financial flexibility with 18.25B yen in cash and deposits against minimal liabilities of 1.01B yen, providing extended operational runway despite ongoing losses. Operating cash flow of -2.99B yen combined with full-year forecast projecting further loss expansion to 5.69B yen suggests near-term profitability is not anticipated, positioning this as an early-stage development story where clinical and regulatory milestones will likely drive future valuation inflection points rather than near-term earnings.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.